A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. The intravenous and oral LD50 were 3.0 and 12.0 g/kg respectively in the mouse and 3.2 and 16.4 g/kg respectively in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog.
An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Alpha-1-proteinase inhibitor | Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminocaproic acid. |
| Menadione | Menadione may increase the thrombogenic activities of Aminocaproic acid. |
| Tranexamic acid | Tranexamic acid may increase the thrombogenic activities of Aminocaproic acid. |
| Aprotinin | Aminocaproic acid may increase the thrombogenic activities of Aprotinin. |
| Hydrogen peroxide | Aminocaproic acid may increase the thrombogenic activities of Hydrogen peroxide. |
| Aminomethylbenzoic acid | Aminocaproic acid may increase the thrombogenic activities of Aminomethylbenzoic acid. |
| Camostat | Aminocaproic acid may increase the thrombogenic activities of Camostat. |
| Menadione bisulfite | Aminocaproic acid may increase the thrombogenic activities of Menadione bisulfite. |
| Tretinoin | The risk or severity of Thrombosis can be increased when Aminocaproic acid is combined with Tretinoin. |
| Antihemophilic factor, human recombinant | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor, human recombinant. |
| Coagulation factor VIIa Recombinant Human | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation factor VIIa Recombinant Human. |
| Coagulation Factor IX (Recombinant) | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation Factor IX (Recombinant). |
| Calcium | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Calcium. |
| Pantothenic acid | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Pantothenic acid. |
| Formic acid | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Formic acid. |
| Platelet Activating Factor | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Platelet Activating Factor. |
| Turoctocog alfa | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Turoctocog alfa. |
| Fibrinogen human | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Fibrinogen human. |
| Catridecacog | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Catridecacog. |
| Antihemophilic factor (recombinant), PEGylated | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor (recombinant), PEGylated. |
| Prothrombin | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Prothrombin. |
| Factor IX Complex (Human) | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Factor IX Complex (Human). |
| Susoctocog alfa | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Susoctocog alfa. |
| Eftrenonacog alfa | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Eftrenonacog alfa. |
| Rusalatide acetate | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Rusalatide acetate. |
| Vatreptacog alfa | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Vatreptacog alfa. |
| Factor XIII (human) | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Factor XIII (human). |
| Von Willebrand factor human | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Von Willebrand factor human. |
| Coagulation factor X human | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation factor X human. |
| Coagulation factor VII human | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation factor VII human. |
| Anti-inhibitor coagulant complex | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Anti-inhibitor coagulant complex. |
| Coagulation Factor IX Human | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation Factor IX Human. |
| Antihemophilic factor human | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor human. |
| Kallidinogenase | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Kallidinogenase. |
| Trenonacog alfa | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Trenonacog alfa. |
| Albutrepenonacog alfa | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Albutrepenonacog alfa. |
| Emicizumab | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Emicizumab. |
| Nonacog beta pegol | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Nonacog beta pegol. |
| Moroctocog alfa | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Moroctocog alfa. |
| Beroctocog alfa | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Beroctocog alfa. |
| Andexanet alfa | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Andexanet alfa. |
| Calcium cation | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Calcium cation. |
| Damoctocog alfa pegol | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Damoctocog alfa pegol. |
| Turoctocog alfa pegol | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Turoctocog alfa pegol. |
| Alteplase | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Alteplase. |
| Urokinase | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Urokinase. |
| Reteplase | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Reteplase. |
| Anistreplase | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Anistreplase. |
| Tenecteplase | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Tenecteplase. |
| Streptokinase | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Streptokinase. |
| Lanoteplase | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Lanoteplase. |
| Amediplase | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Amediplase. |
| Saruplase | The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Saruplase. |
| Protein S human | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Protein S human. |
| Rurioctocog alfa pegol | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Rurioctocog alfa pegol. |
| Etranacogene dezaparvovec | The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Etranacogene dezaparvovec. |